---
figid: PMC11215075__fphar-15-1406493-g005
pmcid: PMC11215075
image_filename: fphar-15-1406493-g005.jpg
figure_link: /pmc/articles/PMC11215075/figure/F5/
number: FIGURE 5
figure_title: ''
caption: 'The proposed hepatic metabolic pathway and altered gene expression by treatment
  with ezetimibe (white arrow) in a rat model of obesity and type 2 diabetes. Abbreviations:
  ACSL1: long-chain acyl-coenzyme A synthetase 1; CCTÎ±: CTP:phosphpocholine cytidylyltransferase
  alpha; DGAT: diacylglycerol acyltransferase; ELOVL5: elongation of very long chain
  fatty acids protein 5; FADS2: fatty acid desaturase 2; FATP5: fatty acid transport
  protein 5; L-FABP: liver fatty acid-binding protein; LPCAT: lysophosphatidylcholine
  acyltransferase; PC: phosphatidylcholine; PE: phosphatidylethanolamine; PEMT: phosphatidylethanolamine
  N-methyl-transferase; PLA2: phospholipase A2; PC-PLC: PC-specific phospholipase
  C.'
article_title: Ezetimibe, Niemann-Pick C1 like 1 inhibitor, modulates hepatic phospholipid
  metabolism to alleviate fat accumulation.
citation: Hyekyung Yang, et al. Front Pharmacol. 2024;15:1406493.
year: '2024'

doi: 10.3389/fphar.2024.1406493
journal_title: Frontiers in Pharmacology
journal_nlm_ta: Front Pharmacol
publisher_name: Frontiers Media S.A.

keywords:
- ezetimibe
- hepatic steatosis
- phospholipids
- metabolomics
- lipidomics

---
